Tuesday, September 28, 2021
- Advertisement -spot_img


Bharat Biotech

Covaxin found to neutralise the India variant, says Dr Fauci

"Now, this is something we are still gaining data on, but most recent data looking at convalescent sera of Covid-19 cases in people who received Covaxin, it was found to neutralise the 617 variant," Fauci was quoted as saying during the White House press briefing

Bharat Biotech responds positively to Telangana’s request

This message was conveyed to Chief Secretary Somesh Kumar who held a meeting with Dr. Krishna Ella, MD, Bharat Biotech on Tuesday at BRKR Bhavan following directions from Chief Minister K. Chandrashekar Rao.

Covaxin priced at Rs 600 for states, Rs 1,200 for pvt hospitals

Bharat Biotech CMD Krishna M Ella said the company is supplying the vaccine to the Central Government at Rs 150 per dosage

Covaxin demonstrates 78% efficacy in phase 3 interim analysis

Safety and efficacy results from the final analysis will be available in June and the final report will be submitted to a peer-reviewed publication, says Bharat Biotech

ICMR says Covaxin can neutralise double mutant Covid variant

The top research institute said that “NIV has also demonstrated the neutralisation potential of Covaxin against the UK and Brazil variants.”

Bharat Biotech takes up Covaxin capacity expansion

Hyderabad-based vaccine maker implements expansion across multiple facilities in Hyderabad and Bengaluru to reach about 700 million doses per year capacity

Brazilian govt’s 20 million dose order is still active: Bharat Biotech

"The agreement with Precisa Medicamentos is based on a long term partnership and will continue,” Bharat Biotech stated.

One year of lockdown: Telangana life sciences industry shows resilience

Soon after the outbreak, the industry quickly adapted to the supply chain needs and manpower scenario and got into making generic drugs and vaccine development.

Covaxin phase 2 data impressive

According to the interim results of the phase 2 trials published in The Lancet Infectious Diseases journal.

54 per cent of Hyderabad’s population developed antibodies against Covid-19: Study

The study showed that 54 per cent of the population in the city has antibodies, which means they have developed immunity to SARS-CoV-2 virus

Bharat Biotech’s Covaxin 81 pc efficient in Phase 3 clinical trials

The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement.

Chinese hackers target SII, Bharat Biotech: Report

Both SII and Bharat Biotech are involved in producing Covid-19 vaccine

NITI Aayog proposes Covid vaccine price between Rs 300-500

However, the union health ministry would take a final call on the proposition.

Bharat Biotech signs deal with Brazil to supply Covaxin

Hyderabad-based vaccine maker to supply 20 million doses of Covaxin during the second and third quarters of 2021

Ukraine Health Minister visits Bharat Biotech facility

The representatives from the Central Asian nation of 41 million people took a tour of the world-class Bio-Safety Level 3 manufacturing facility.

Pandemic bolstered Hyderabad’s role as vaccine capital of the world: KTR  

Life sciences sector in Telangana attracted investments to the tune of about Rs 3,700 crores in last one year with an employment potential for around 14,000 people

Stage set for BioAsia 2021 virtual conference

This year's edition to be held virtually

BioAsia ’21 announces Genome Valley Excellence award to Bharat Biotech

Dr Krishna M Ella, CMD and Suchitra Ella, joint managing director, Bharat Biotech International will receive the award on February 22, during the inaugural event of BioAsia 2021.

Second shot of Covid-19 vaccine for Telangana health workers from Saturday

2,77,825 inoculated as first phase of vaccine drive in State concludes

Bharat Biotech, Ocugen ink pact for commercialisation of Covaxin in US

Under the terms of the agreement, Ocugen will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including emergency use authorisation (EUA)) and commercialisation for the US market.

Latest news

- Advertisement -spot_img
Telangana Today